In a new study that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have adapted a chemical approach to turn diseased cells into unique manufacturing sites for molecules that can treat a form of muscular dystrophy.
“We’re using a cell as a reaction vessel and a disease-causing defect as a catalyst to synthesize a treatment in a diseased cell,” said TSRI Professor Matthew Disney. “Because the treatment is synthesized only in diseased cells, the compounds could provide highly specific therapeutics that only act when a disease is present. This means we can potentially treat a host of conditions in a very selective and precise manner in totally unprecedented ways.”
The promising research was published recently in the international chemistry journal Angewandte Chemie.
Targeting RNA Repeats
In general, small, low molecular weight compounds can pass the blood-brain barrier, while larger, higher weight compounds tend to be more potent. In the new study, however, small molecules became powerful inhibitors when they bound to targets in cells expressing an RNA defect, such as those found in myotonic dystrophy.
Myotonic dystrophy type 2, a relatively mild and uncommon form of the progressive muscle weakening disease, is caused by a type of RNA defect known as a “tetranucleotide repeat,” in which a series of four nucleotides is repeated more times than normal in an individual’s genetic code. In this case, a cytosine-cytosine-uracil-guanine (CCUG) repeat binds to the protein MBNL1, rendering it inactive and resulting in RNA splicing abnormalities that, in turn, results in the disease.
In the study, a pair of small molecule “modules” the scientists developed binds to adjacent parts of the defect in a living cell, bringing these groups close together. Under these conditions, the adjacent parts reach out to one another and, as Disney describes it, permanently hold hands. Once that connection is made, the small molecule binds tightly to the defect, potently reversing disease defects on a molecular level.
“When these compounds assemble in the cell, they are 1,000 times more potent than the small molecule itself and 100 times more potent than our most active lead compound,” said Research Associate Suzanne Rzuczek, the first author of the study. “This is the first time this has been validated in live cells.”
The Latest on: Specific therapeutics
via Google News
The Latest on: Specific therapeutics
- Pear Therapeutics launches digital insomnia app through direct-to-patient telehealth modelon November 18, 2020 at 7:42 am
Pear Therapeutics has launched its prescription smartphone app for chronic insomnia, designed to help train the brain and body to get a better night’s sleep.
- InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeuticson November 18, 2020 at 4:49 am
Under the terms of the Collaborative Research Agreement, BayMedica is being provided access to specific elements of InMed's proprietary IntegraSyn TM platform for the production of cannabinoids.
- Novus Therapeutics, Inc. (NVUS) CEO David-Alexandre Gros on Q3 2020 Results - Earnings Call Transcripton November 17, 2020 at 12:04 am
NVUS) Q3 2020 Earnings Conference Call November 16, 2020 04:30 PM ET Company Participants Jon Kuwahara - Senior Vice President of Finance David-Alexandre Gros - Chief Executive Officer Steve Perrin - ...
- TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conferenceon November 16, 2020 at 9:00 pm
TG Therapeutics, Inc., today announced that Michael S. Weiss, the Company’ s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the Jefferies Virtual London ...
- Jounce Therapeutics Receives Study May Proceed Letter from US FDA to Initiate Phase 1 Clinical Trial of JTX-8064 Targeting the LILRB2/ILT4 Mechanismon November 16, 2020 at 5:22 am
Phase 1 INNATE trial will evaluate JTX-8064 as a monotherapy and in combination with Jounce’s PD-1 inhibitor, JTX-4014--On track to begin ...
- Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical developmenton November 16, 2020 at 5:16 am
Alligator Bioscience, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy and Aptevo Therapeutics Inc., a biotechnology company focused on developing ...
- Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020on November 16, 2020 at 4:41 am
Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020 * Pre-clinical safety data show no adverse or off-target effects and targeted biodistribution o ...
- Harpoon Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conferenceon November 16, 2020 at 4:32 am
(GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President ...
- Silence Therapeutics Presents Positive Pre-Clinical Data for SLN360 for the Treatment of ...on November 16, 2020 at 4:02 am
Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) at American Heart Association 2020. Pre-clinical safety data show ...
- Silverback Therapeutics Starts IPO Rollouton November 13, 2020 at 6:47 pm
Get them exclusively at IPO Edge. Get started today » Silverback Therapeutics ( SBTX) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The ...
via Bing News